2024
Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics. Blood 2024, 144: 4267-4267. DOI: 10.1182/blood-2024-202744.Peer-Reviewed Original ResearchMorphologic leukemia-free stateComposite complete remissionTreated with ICIntensive chemotherapyMonosomal karyotypeComplex karyotypeProgressive diseaseSurvival outcomesTreatment strategiesAllogeneic hematopoietic stem cell transplantationComposite complete remission rateTreated with intensive chemotherapyHematopoietic stem cell transplantationComparative analysis of outcomesDismal survival outcomesConventional cytotoxic chemotherapyAggressive disease biologyMulticenter retrospective cohortStem cell transplantationAnalyze survival outcomesKaplan-Meier methodLog-rank testAnalysis of outcomesCK-AMLCPX-351
2023
Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax
Shimony S, Garcia J, Keating J, Chen E, Luskin M, Stahl M, Neuberg D, DeAngelo D, Stone R, Lindsley R. Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax. Blood 2023, 142: 977. DOI: 10.1182/blood-2023-173935.Peer-Reviewed Original ResearchComposite complete response rateComposite complete responseHematopoietic cell transplantationAcute myeloid leukemiaDe novo groupHypomethylating agentsOverall survivalComplete responseTP53 mutationsPrognostic valueNewly diagnosed acute myeloid leukemiaAssociated with improved OSTreated with hypomethylating agentsTreated with intensive chemotherapyAllogeneic hematopoietic cell transplantationDiagnosed AMLMultivariate Cox regression modelConcurrent TP53 mutationLow-intensity regimensDiagnosed AML patientsLog-rank testRetrospective cohort studyMolecular ontogenyDe novo diseaseDana Farber Cancer Institute
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply